neel1002 said:
Supratik.........
I Am A Fan Of Your Analysis. Boss, Could You Please Help Me By Giving Your View On Shasun Chemicals For A Mid-term Perspective ?
Hi,
I am no analyst my friend, I buy on News and to be honest I am very poor in reading charts and Balance Sheets...anyway thanks for your compliments
I would say my view on Shashun Chemicals and Drugs is a buy in small quantities and on regular intervals.
The following would provide you some additional info, which I thought would enhance your knowledge on this counter.
Shasun-The one stop Pharmaceutical Shop, Integrated, Diverisified,
Collaborative.
-From gm to multi-tonnes to Finished Dosages
-Each Business Unit is an independent offering
-Combinations available to pick and choose from.
-Shasun offers contract development, contract manufacturing, Excipients, APIs, Generics, formulations and Biotechnology (Recombinant Proteins).
-Shasun, Cuddalore spread over 44,000 sq metres offers CRAMS facility.
-Shasun Biotech Center spread over 2025 sq metres offers capability to handle fermentation reactions, and recombinant Biotechnology.
-Shasun R&D Facility- Phase I cGMP Class 10000 scale up laboratory, with 12 Organic Chemistry Modular Labs.
-Low Debt Equity of 0.65
-Percentage of CRAM products rising, Generics include Ibuprofen (anti-inflamatory), Ranitidine and Nizatidine (Anti-Ulcer), with global leadership.
-New Products launched-Gabapentin (Anti-Emetic, CNS) product being readied for supply to Eli Lilly US, a $ 700 mn global demand for treatment of epilepsy and neurological disorders.
-APIs being readied for Codexis, USA, scale up and commercial quantities for Non Regulated markets commenced in Q3.
-Shasun has moved into a new R&D facility, which can handle large volumes of CRAMS, during FY06 expects a year on year growth of 25 per cent.
-Low PE of 13 on forecast FY06 e earnings of Rs 8 per share (FV Rs 2)
-A Small Equity of Rs 9.6 crore
-A marginal increase in PE will take the scrip to Rs 120.
BUY
Stock now has a FV of Rs 2, consequently FY05 EPS is not comparable.
Type UnAudited UnAudited UnAudited Audited UnAudited
Date Begin 01 Oct 05 01 Jul 05 01 Apr 05 01 Jan 05 01 Oct 04
Date End 31 Dec 05 30 Sep 05 30 Jun 05 31 Mar 05 31 Dec 04
Description Value(Rs. million)
Gross Sales 1023.9 873.3 772.6 1058 781.1
Excise Duty -31.2 -29.2 -22.5 -22 -23.2
Net Sales 992.7 844.1 750.1 1036 757.9
Other Income 2.4 2.9 1.8 3.8 1.3
Total Income 995.1 847 751.9 1039.8 759.2
Expenditure -789.4 -698.3 -628.4 -778.4 -578.2
Operating Profit 205.7 148.7 123.5 261.4 181
Interest -12.9 -13.1 -12.9 -11.7 -8.4
Gross Profit 192.8 135.6 110.6 249.7 172.6
Depreciation -61.2 -57.9 -52 -70.6 -48.3
Profit before Tax 131.6 77.7 58.6 179.1 124.3
Tax -2.6 -15.8 -16 -55 -34.2
Profit after Tax 129 61.9 42.6 124.1 90.1
Net Profit 129 61.9 42.6 124.1 90.1
Equity Capital 96.1 91.6 91.6 91.5 91.4
EPS 2.71 1.35 4.65 13.57 9.86
Nos. of Shares - Non Promoters 27692672 27440822 5417430 5420420 5413654
Percent of Shares - Non Promoters 57.64 59.92 59.15 59.22 59.23
Thanks and Regards
Supratik
if i remember correctly , and i am in far east in the land of rising sun. We can plan a treat somewhere mid-way . 